Recent Announcements

Oct 31, 2017

Cellect chosen among selected global leaders presenting at Bio-Europe 2017

addressing over 3,800 industry specialists from over 2,000 world leading companies

Sep 05, 2017

FDA Grants Orphan Drug Status to Cellect’s ApoGraft™ for Acute GvHD and Chronic GvHD

June 14, 2017

Following the US, Cellect Receives Russian Patent Covering Any Device and Method Using Cellect's Flagship Technology - the ApoGraft™

June 12, 2017

Cellect Receives Notice of Allowance from the US Patent & Trademark Office


June 09, 2017

Cellect is Moving to Trade Exclusively on the NASDAQ

Jan 30, 2017

Dr. Yaron Pereg Appointed as New Chief Development Officer

Ex BioLineRx, Genentech Inc., Glusense and others

Jan 09, 2017

Major shareholder buying shares

Michael Ilan Management and Investment Ltd.increases holdings to 15.7%

Jan 01, 2017

Cellect Announces Appointment of Eyal Leibovitz, Experienced Life Sciences Industry and Financial Executive, as Chief Financial Officer

Join our mailing list

Submitting Form...

The server encountered an error.

Form received. Thank you.

© 2017 Cellect Biotherapeutics Ltd., all rights reserved  | CODE OF ETHICS